Authors

Latest:

Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Benjamin Besse, MD

Latest:

The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Benjamin Besse, MD, PhD, Gustave Roussy

Benjamin Besse, MD, PhD, Institut d'Oncologie Thoracique

Benjamin D. Smith, MD

Latest:

Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer

Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.

Benjamin Heyman, MD

Latest:

Dr. Heyman on the ALPINE Trial in CLL

Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.

Benjamin L. Ebert, MD, PhD

Latest:

Research Findings Point to Clinical Importance of Clonal Hematopoiesis

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.

Benjamin L. Lampson, MD, PhD

Latest:

Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL

Benjamin L. Lampson, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, discusses preliminary safety and efficacy results from a phase II study of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Benjamin Leon Musher, MD

Latest:

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Latest:

Refining EGFR Classifications and Impact on Treatment for NSCLC

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale

Latest:

Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

Benjamin Levy, MD, Mount Sinai Health Systems,

Benjamin Levy, MD, Mount Sinai Hospital

Benjamin Maughan, MD

Latest:

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Benjamin Maughan, MD, PharmD

Latest:

Triple Combination Therapies in RCC: Clinical Trial Insights

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Benjamin O. Anderson, MD

Latest:

Dr. Anderson on the Unmet Need in Low- and Middle-Income Breast Cancer Care

Benjamin O. Anderson, MD, a surgical oncologist at the Seattle Cancer Care Alliance, discusses the biggest unmet need for patients with breast cancer in low- and middle-income countries.

Benjamin P. Levy, MD

Latest:

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center

Latest:

Uncommon EGFR Mutations in NSCLC: Real-World Selection and Use of Novel Agents

Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.

Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

Latest:

Evolving Field of Molecular Testing in Non–Small Cell Lung Cancer

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

Benjamin P. Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Latest:

Uncommon EGFR Mutations in NSCLC: Future Directions in Care

Closing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.